-
On December 5, the pharmaceutical industry received a net purchase of nearly 1.2 billion yuan, and a number of shares received a net purchase of more than 100 million yuan
Time of Update: 2023-01-01
According to the Flush Data Center, Xinhua Pharmaceutical received financing to buy 155 million yuan on December 5, accounting for 18.
On December 5, Tongce Medical received financing to buy 103 million yuan, accounting for 15.
-
Over $2 billion! Regeneron collaborates with CytomX to develop a new generation of dual antibodies
Time of Update: 2023-01-01
On November 17, Regeneron and CytomX Therapeutics announced a collaboration and license agreement to develop conditionally activated experimental next-generation bispecific cancer therapies using CytomX's Probody therapeutic platform and Regeneron's Veloci-Bi bispecific antibody development platform.
-
The Chinese pharmaceutical company's "going overseas" continues to accelerate, and another vaccine of the company has been approved in Indonesia
Time of Update: 2023-01-01
js?cdnversion='+~(-new Date()/36e5)];In recent years, with the continuous enhancement of innovation strength, more and more Chinese innovative pharmaceutical companies are on the road of accelerating "going to sea".
-
More than 30 pharmaceutical companies have seen significant shareholder reductions, and these companies have the largest amount of shareholding
Time of Update: 2023-01-01
According to statistics, in November, the directors, supervisors and related persons of listed companies in Shanghai and Shenzhen reduced their holdings by a total of about 5.
-
Capital market A and A are active, and two pharmaceutical companies are "married"!
Time of Update: 2023-01-01
js?cdnversion='+~(-new Date()/36e5)];China Resources Sanjiu announced on November 29 that the company will plan to acquire KunYao Group for 2.
js?cdnversion='+~(-new Date()/36e5)];China Resources Sanjiu announced on November 29 that the company will plan to acquire KunYao Group for 2.
-
Ningbo Municipal Supervision Bureau: Fine up to 5 million yuan for manipulating the market price of medical supplies
Time of Update: 2023-01-01
Ningbo Market Supervision WeChat public account news, Ningbo Market Supervision Administration issued the "Reminder on the Price Behavior of Medical Drugs and Supplies" on the 6th. It is proposed that
-
The improvement of the quality of Chinese medicine pieces still needs to be accelerated, and the upstream pharmaceutical machine industry may be affected
Time of Update: 2023-01-01
In order to strengthen drug quality supervision and ensure the safety of public drug use, local drug regulatory departments are conducting frequent supervision and sampling inspections on the quality
-
The overseas expansion of domestic pharmaceutical equipment is accelerating, and the development of high-end market will become a general trend
Time of Update: 2023-01-01
The development of domestic pharmaceutical equipment to the high-end market will become a general trend (Image source: Pharmaceutical Network) For example, over the years, while continuing to expand its product line and comprehensively layout in the fields of engineering, equipment and consumables, Dongfulong has been establishing overseas R&D and design centers, and is committed to becoming a world-class pharmaceutical overall solution provider.
-
To achieve import substitution of biopharmaceutical equipment, it is necessary to continuously promote development with quality and innovation
Time of Update: 2023-01-01
To achieve import substitution of biopharmaceutical equipment, it is necessary to promote development with quality and innovation (Image source: Pharmaceutical Network) At present, the development of the biopharmaceutical industry is clearly thriving.
-
Listed companies continue to increase share buybacks, and pharmaceutical companies are also setting off a "buyback tide"
Time of Update: 2023-01-01
78 yuan / share, and the total amount of funds paid was 150 million yuan (excluding stamp duty, transaction commissions and other transaction 。 On December 1, CanSino announced that as of November 30, the company had repurchased a total of 670,100 A shares in a centralized bidding transaction, accounting for 0.
-
Another pharmaceutical company launched a "1 yuan purchase" employee stock ownership plan!
Time of Update: 2023-01-01
js?cdnversion='+~(-new Date()/36e5)];Ruikang Pharmaceutical announced on the evening of December 6 that the company intends to launch the 2022 employee stock ownership plan, the total number of employees participating in this employee stock ownership plan will not exceed 108, and the purchase price of the company's repurchased shares is 1 yuan per share.
-
Single-use pressure monitoring magnetic positioning radiofrequency ablation catheter approved for marketing
Time of Update: 2023-01-01
The product adopts pressure sensing technology, magnetic field positioning technology, head porous saline perfusion technology and three-dimensional electrophysiological mapping system based on the principle of strain gauges, which can provide an overall solution for the treatment of patients with atrial fibrillation, and is the first cardiac radiofrequency ablation catheter with pressure sensing function in China.
-
National Action Plan to Curb Microbial Resistance (2022-2025)
Time of Update: 2023-01-01
All provinces, autonomous regions, municipalities directly under the Central Government, and the Xinjiang Production and Construction Corps Health Commission, Education Department (Education Commissi
-
The concept of ursodeoxycholic acid suddenly became popular, and pharmaceutical companies issued announcements in response
Time of Update: 2023-01-01
js?cdnversion='+~(-new Date()/36e5)];On December 7, the concept stock of ursodeoxycholic acid broke out across the board, with Sinotherapeutics and Gonggong Pharmaceutical gaining a 20CM price limit, and Shuangcheng Pharmaceutical and Qianhong Pharmaceutical gaining a limit.
-
In order to expand production capacity, it has become normal for pharmaceutical companies to invest in the construction of new production lines
Time of Update: 2023-01-01
This is the second fully automated isolation sterile injection production line put into operation by Heqing Pharma this year, with an annual production capacity of 10 million injections, which means that the company continues to improve the capacity of the aseptic injection platform.
-
A gift of centenarian heparin! The first crude heparin GMP guide is here
Time of Update: 2023-01-01
Recently, the national group information platform and the China Biochemical Pharmaceutical Industry Association simultaneously released the "Crude Heparin Production Quality Management Guide" (T/CBPI
-
Raw materials up to 10,000! 4 consecutive rounds in a week! Many places announced the cancellation of control and the resumption of production and operation! Dozens of chemical raw materials rush high!
Time of Update: 2023-01-01
com" style="margin: 0px; padding: 0px; outline: 0px; max-width: 100%; box-sizing: border-box; overflow-wrap: break-word; ">Source: Waterborne Big PlatformAfter 4 consecutive rounds of rise, global gas prices climbed collectivelyGlobal natural gas prices continue to rise as temperatures continue to drop, resulting in strong demand for natural gas.
-
In December, a number of IPOs were applied for and listed in the pharmaceutical industry
Time of Update: 2022-12-30
According to the company's announcement on December 2, all the shares issued this time are new shares, the initial number of shares issued is 15 million, and the total share capital after issuance is 83.
-
Pharmaceutical biology is optimistic, and these companies have been frequently investigated recently
Time of Update: 2022-12-30
js?cdnversion='+~(-new Date()/36e5)];In the past week, the number of listed companies surveyed by disclosed institutions reached 190 (compared to 205 in the previous week), focusing on machinery and equipment, medicine and biology, electronics, basic chemicals, computers, automobiles and other industries.
-
Domestic pharmaceutical enterprises are vigorously promoting the construction of industrialization bases, and investment of 100 million yuan has become the norm
Time of Update: 2022-12-30
With the wave of innovation in the pharmaceutical industry, many enterprises are accelerating projects such as building new R&D production bases in order to improve profitability, enhance innovative
